Navigation Links
Influenza Vaccine FluMist To Be Approved In Younger Children As Well

MedImmune, the company that has successfully sold flu vaccines to healthy adults in the age range of 5 to 49 is now poised on the edge of another victory . The U.S Food and Drug Administration is now about to approve the sale of FluMist targeting children younger than 5 years.

This announcement comes at a time when the company is planning to self itself to UKs AstraZeneca for 15.6 billion dollars. AstraZeneca was behind MedImmune because it did not have its own flu vaccine business. Once the deal closes, MedImmune becomes a wholly owned subsidiary of AstraZeneca.

The vaccine FluMist has had more than its share of hurdles, such as the preliminary safety concerns, being deemed unfit for young kids, and then storage problems as most pharmacies refused the drug as it needed to be stored in the freezer. This was overcome recently by a FDA-approved refrigerator safe version.

The newer version of MedImmune s FluMist appears effective for children younger than 5 years old, although safety data on the influenza vaccine is still under examination.

MedImmune sought FDA approval to market the spray for children ages 1 to 5 without a history of wheezing or asthma.

According to FDA documents, four studies conducted by MedImmune found the drug was effective against Type A and B influenza viruses, including one trial that showed the vaccine was about 90 percent effective.

Reviewers for the FDA also said one company study of the nasal spray vaccine did not signal any widespread safety problems, but results from other studies are still being reviewed. Those findings will be presented to the panel on Wednesday.

Though children who received FluMist experienced more wheezing than those who were given an inactive vaccine, "the difference between treatment groups is quite small," one reviewer said.

Other side effects included pneumonia, among other problems. Previously known side effects with FluMis t include nasal congestion, runny nose, sore throat and cough.

In a separate document, MedImmune claimed the vaccine's safety and efficacy were proven in children 24 to 59 months old and "that the risk-benefit profile for children 12 (to) 23 months of age without a history of wheeze or asthma warrants use of FluMist in this population as well."

It also said it would continue to monitor the drug in younger patients if approved.

FluMist competes with injectable flu vaccines made by GlaxoSmithKline Plc, Sanofi-Aventis' Sanofi Pasteur unit, and Chiron, which was recently acquired by Novartis AG.


'"/>




Related medicine news :

1. Influenza drug delayed
2. Chances are high for Avian Influenza virus altering its form
3. Influenza Avian Flu strain has become more contagious and dangerous.
4. A Vaccine for the impending pandemic Avian Influenza
5. Influenza Vaccination for children with neurological or neuromuscular disease
6. Avian Influenza: Government to set up expert committee
7. Resistant Influenza strains creates panic in US
8. Influenza Vaccination For The Elderly
9. Fao Declares Humans Spread Avian Influenza Virus
10. Statins Could Play Important Role In Influenza Pandemic
11. Zoo Animal Succumbs to Avian Influenza in Germany
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital Tampa Wound ... Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the ... hospitals and facilities have earned this distinction. This is the second time the ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s ... groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced ... J. Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the ... series, and attorneys from the firm’s global Life Sciences & Medical Technology Group have ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... MOUNTAIN VIEW, Calif. , Dec. 8, 2016 ... it intends to offer newly issued shares of common stock, ... "Shares") pursuant to an underwritten public offering.  The final terms ... at the time of pricing, and there can be no ... completed. IRIDEX expects to use the net proceeds ...
(Date:12/8/2016)... -- Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices Market Outlook to 2022", provides ... Devices market. The report provides value, in millions ... prices (USD) within market segement - Glaucoma Drainage ... and distribution shares data for each of these ...
(Date:12/8/2016)...  The global biosurgery market is expected to grow ... of 2016 to 2021. The market is poised to ... billion in 2016. The market is primarily driven by ... injuries and spinal problems, increasing clearance of biosurgery products ... loss management. In this report, the biosurgery ...
Breaking Medicine Technology: